How Beiing rates peptide evidence

Every individual peptide page on Beiing carries one of five labels: FDA Approved, Human Evidence, Early Research, Insufficient Evidence, or Safety Concerns. The label describes the state of the published evidence and regulatory record. It is never a recommendation, and it never implies a compound is suitable for you.

The five evidence labels used on every Beiing peptide page, and what each one requires of the published research and regulatory record.

One label per compound, describing the published record rather than our opinion of it.

Key takeaways

The five levels

FDA Approved. The compound is approved by the U.S. Food and Drug Administration for at least one specific indication, with a reviewed safety and efficacy record. The approval is specific; other uses are not covered by it.

Human Evidence. Published clinical trials in people exist. Findings may be limited, mixed, small, or outside any approved use, but people have been studied.

Early Research. Evidence comes mainly from cell culture, animal models, or very small human studies. Results at this stage do not reliably predict clinical outcomes.

Insufficient Evidence. There is not enough published research to say whether the compound does what people claim.

Safety Concerns. Regulators or published reports have raised specific safety issues. Risk leads the record, and the page is written accordingly.

How a label is assigned

We look first at regulatory status in the United States, then at whether randomised human trials exist and what they measured, then at whether findings have been independently replicated. Where a compound would fit two labels - approved for one indication but unstudied for the use it is marketed for - the page states both, and the badge reflects the regulatory reality.

What the labels are not

A label is not a rating of how well something works for you, a suggestion to try it, or a substitute for a clinician's judgement. An FDA Approved badge on a page does not mean the medicine is appropriate for any particular person, and an Early Research badge does not mean a compound will eventually be proven useful.

What Beiing will not publish

Across this entire section, regardless of evidence level:

Frequently asked questions

Why not just rank peptides best to worst?

Because that would answer a question the evidence cannot answer. The labels describe how much is known, which is a different and more honest measurement.

How often are labels reviewed?

Labels are checked against the current FDA record when a page is updated. The review date is shown on each page.

Why is there no dosing information anywhere on Beiing?

Dosing is a clinical decision that depends on the person, the indication and monitoring. Publishing it for unapproved compounds would also amount to instructions for using unregulated drugs.

Related on Beiing

Sources

  1. FDA - Drug Approvals and Databases - U.S. Food and Drug Administration
  2. FDA - Bulk Drug Substances Used in Compounding Under Section 503A - U.S. Food and Drug Administration
  3. ClinicalTrials.gov - U.S. National Library of Medicine

Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.